Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Cash Flow (2023 - 2025)

CG Oncology (CGON) has disclosed Net Cash Flow for 3 consecutive years, with -$12.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 105.92% year-over-year to -$12.6 million, compared with a TTM value of -$224.5 million through Dec 2025, down 190.25%, and an annual FY2025 reading of -$224.5 million, down 190.25% over the prior year.
  • Net Cash Flow was -$12.6 million for Q4 2025 at CG Oncology, down from $30.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $213.7 million in Q4 2024 and bottomed at -$215.6 million in Q1 2025.
  • Average Net Cash Flow over 3 years is -$4.6 million, with a median of -$7.3 million recorded in 2023.
  • The sharpest move saw Net Cash Flow skyrocketed 10745.59% in 2024, then plummeted 411.55% in 2025.
  • Year by year, Net Cash Flow stood at -$2.0 million in 2023, then surged by 10745.59% to $213.7 million in 2024, then plummeted by 105.92% to -$12.6 million in 2025.
  • Business Quant data shows Net Cash Flow for CGON at -$12.6 million in Q4 2025, $30.6 million in Q3 2025, and -$26.8 million in Q2 2025.